Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of SYS6010 plus PD-(L)-1 antibody versus PD-(L)-1 antibody alone as adjuvant therapy in resected stage II-IIIB driver-negative non-small cell lung cancer without major pathologic response
CTR20262461Phase 3Active
- Sponsor
- CSPC Megalith Biopharmaceutical Co., Ltd.
- Start
- Jun 2026
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of CPO301, tislelizumab, toripalimab, durvalumab, pembrolizumab in non-small cell lung cancer (NSCLC), sponsored by CSPC Megalith Biopharmaceutical Co., Ltd.. Started Jun 2026; status: active.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20262461.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262461.